4D Molecular Therapeutics (FDMT) vs Olema Pharmaceuticals (OLMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed Olema Pharmaceuticals (OLMA) over the past year, gaining 51.3% versus a loss of 23.9%. Over five years, FDMT leads with a -53.9% price change compared with -74.1% for OLMA. 4D Molecular Therapeutics is the larger company by market cap ($695.5 million vs $694.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | OLMA |
|---|---|---|
| Share price | $12.59 | $7.94 |
| Market cap | $695.52M | $694.73M |
| 1-day change | +0.24% | +0.25% |
| YTD return | +67.87% | -68.24% |
| 1-year return | +51.32% | -23.95% |
| 5-year return | -53.92% | -74.15% |
| EPS (TTM) | $-2.63 | $-2.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $36.26 |
| 52-week low | $6.96 | $6.65 |
| Distance from 52-week high | -25.63% | -78.10% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +123.11% | +359.70% |
| Average volume | 924.05K | 1.06M |
| Shares outstanding | 55.24M | 87.50M |
| Employees | 196 | 150 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed OLMA by 75.3 percentage points over the past year.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Olema Pharmaceuticals
OLMA stock →Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 150 employees
FDMT vs OLMA FAQ
Which is bigger, 4D Molecular Therapeutics or Olema Pharmaceuticals?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $695.52M compared with $694.73M for Olema Pharmaceuticals (OLMA).
Which stock has performed better over the past year, FDMT or OLMA?
FDMT returned +51.32% over the past 12 months, compared with -23.95% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and Olema Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for 4D Molecular Therapeutics and Biotechnology: Pharmaceutical Preparations for Olema Pharmaceuticals.